

S 607

EFFECTIVE Act

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Mar 1, 2023

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Mar 1, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/607>

Sponsor

Name: Sen. Manchin, Joe, III [D-WV]

Party: Independent • **State:** WV • **Chamber:** Senate

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Braun, Mike [R-IN]	R · IN		Mar 1, 2023
Sen. Baldwin, Tammy [D-WI]	D · WI		Sep 13, 2023

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Mar 1, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 1375	Identical bill	Mar 10, 2023: Referred to the Subcommittee on Health.

Summary (as of Mar 1, 2023)

Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act

This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.

Actions Timeline

- **Mar 1, 2023:** Introduced in Senate
- **Mar 1, 2023:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.